

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

FLATWING PHARMACEUTICALS, LLC and
MYLAN PHARMACEUTICALS, INC.,
Petitioners,

v.

ANACOR PHARMACEUTICALS, INC.,
Patent Owner.

Case No. IPR2018-00169
(Joined with IPR2018-01359)

U.S. Patent No. 9,566,289

**PETITIONER'S REPLY TO PATENT OWNER'S OPPOSITION
TO PETITIONER'S MOTION TO EXCLUDE¹**

February 15, 2019

¹ Corresponding replies to Patent Owner's oppositions filed in related proceedings IPR2018-00168 (U.S. Patent No. 9,549,938, joined with IPR2018-01358), IPR2018-00170 (U.S. Patent No. 9,566,290, joined with IPR2018-01360), and IPR2018-00171 (U.S. Patent No. 9,572,823, joined with IPR2018-001361) are substantially the same as this reply, with citations adjusted to cite correctly the record in each proceeding.

TABLE OF CONTENTS

Table of Contents i

Table of Authorities ii

Discussion.....1

Improper Direct Expert Testimony (37 C.F.R. 42.53, FRE 702–703)3

Hearsay (FRE 801–802).....4

Improper Impeachment4

Authentication (FRE 901)5

Conclusion.....5

Certificate of Service.....7

TABLE OF AUTHORITIES

CASES

CaptionCall, LLC v. Ultratec, Inc.,
IPR2013-00540, Paper 80,
2015 WL 9599187 (P.T.A.B. Dec. 1, 2015).....4

Goguen v. Textron, Inc.,
234 F.R.D. 13 (D. Mass. 2006)5

Marvel Characters, Inc. v. Kirby,
726 F.3d 119 (2d Cir. 2013)4

United States v. Starks,
515 F.2d 112 (3d Cir. 1975)5

RULES

FRE 7024

FRE 7034

FRE 8014

FRE 8024

FRE 9015

FRE 9025

REGULATIONS

37 C.F.R. § 42.205

37 C.F.R. § 42.225

37 C.F.R. § 42.534

DISCUSSION

Petitioner's motion (*Petitioner's 37 C.F.R. § 42.64(c) Motion To Exclude*, Paper 27 (hereinafter "*Pet. Mot. Excl.*")) identified for every exhibit sought to be excluded the specific content that Patent Owner offered as hearsay testimony for the truth of the matter asserted. Patent Owner's opposition (Paper 29) did not respond to any of that, but instead merely asserts in conclusory fashion that its experts "cite to these publications as relevant evidence of the state of the art" (*Patent Owner's Opposition to Petitioner's Motion to Exclude 2*, Paper 29 (hereinafter "*PO Opp.*")), that they are "preexisting documentary evidence" (*id.* at 2), and that they "go to what a POSA would have known at the time of the invention" (*id.* at 4). But patent owner previously admitted that it cited scientific literature "after the priority date" (*Patent Owner's Response 1*, Paper 13 (hereinafter "*PO Resp.*")) about alleged "problems with transungual delivery" (*id.*). Exhibits 2004, 2005, 2006, 2008, 2015, 2016, 2026, 2028, 2035, and 2036 all purport to be dated *after* the asserted 2005 priority date of the patent in suit. They are *not* "preexisting documentary evidence" as Patent Owner claims (*PO Opp. 2*, Paper 29). They are not prior art disclosures independently operative in defining the state of the art as of the asserted 2005 priority date. Instead, Patent Owner relies on them for the truth of the opinions asserted by the authors in those articles, as identified in *Pet. Mot. Excl.* and below. Even for the other articles dated before

the priority date, Patent Owner did not use them to establish the state of the art but instead tried to use specific assertions in those articles for the truth of the matters asserted, as identified in *Pet. Mot. Excl.* and below.

Patent Owner and its experts repeatedly cite *all* of the exhibits to be excluded not for disclosures constituting the state of the art in 2005, but instead as supposed evidence demonstrating the truth of the matters asserted as opinions of the authors of those articles. As identified in *Pet. Mot. Excl.*, those matters asserted include: in Ex. 2004 that the nail is a “formidable barrier”; in Ex. 2005 about the supposed “inability to deliver a therapeutically effective amount”; in Ex. 2006 about supposed “poor drug diffusion into the highly keratinized nail plate and the long duration of treatment” (even though tavaborole itself also has a 48-week long treatment duration (Ex. 1042 at 2)); in Ex. 2007 that “topical therapy continues to pose a challenge”; in Ex. 2008 about “factors that could limit the accumulation and activity of drugs in the nail on topical application”; in Ex. 2009 for having been cited in Ex. 2007 about molecules larger than 300 Daltons facing hindrance in permeating the nail plate; in Ex. 2015 that VELCADE® was “the only boron-based therapeutic currently on the market” in 2009; in Ex. 2016 that the “ultimate fate of all boronic acids in air and aqueous media is their slow oxidation into boric acid”; in Exs. 2019 & 2020 about the alleged consequences of boron’s ability to form complexes; in Exs. 2021, 2022, and 2023 about alleged consequences of boron’s

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.